Drug Discovery
ByIs Short-Term Cost Control Undermining Long-Term Innovation? Novartis Calls for Structural Reform in Global Healthcare
23 January 2026 Executive Summary Novartis has issued a call for structural reform in global healthcare policy, warning…
Is Regional Distribution Becoming a Strategic Lever for Big Pharma? Novartis Expands European Reach Through Malta Partnership
23 January 2026 Executive Summary Novartis Pharma Services AG has entered into a strategic distribution agreement with Vivian…
Can Localized Manufacturing Shield Big Pharma from Trade Volatility? Novartis Targets Zero U.S. Tariff Exposure by Mid-2026
23 January 2026 Executive Summary Novartis CEO Vas Narasimhan has outlined a decisive trade-risk mitigation strategy, stating that…
Is U.S. Manufacturing the Next Growth Hedge for Big Pharma? Novartis Commits $23 Billion to Domestic Expansion
23 January 2026 Executive Summary Novartis has unveiled a $23 billion investment plan to significantly expand its U.S.…
What If HER2 Resistance Was Over? Henlius Doses First Patient in Phase 2/3 HLX22 Trial, Unleashing Multi-Oncology Disruption
Shanghai, China – March 3, 2026 – Henlius Biotech, Inc. (HKEX: 2696), a global biopharmaceutical leader in oncology innovation,…
BMS’s Chinese-Licensed ADC CC-1234 Delivers 52% ORR, 14-Month PFS in Aggressive HER2-Low Breast Cancer
Published by BioNextAI Media – Bristol Myers Squibb (NYSE: BMY) unveiled compelling Phase 2 data for CC-1234, its next-generation…
